Inflammatory bowel disease in the elderly

Drugs and Aging

Volumn 27, Issue 8, 2010, Pages 617-624

  Hussain, Syed Wasif ^a   Pardi, Darrell S ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

azathioprine; ciclosporin; corticosteroids; crohns disease; elderly; hydrocortisone; inflammatory bowel diseases; infliximab; mercaptopurine; mesalazine; methotrexate; prednisone; therapeutic use; treatment; tumour necrosis factor inhibitors; ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ADALIMUMAB; ALLOPURINOL; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; ANTIINFLAMMATORY AGENT;

CARDIOVASCULAR RISK; CLINICAL FEATURE; CROHN DISEASE; DEHYDRATION; ENTERITIS; FECES INCONTINENCE; HUMAN; ILEOSTOMY; PRIORITY JOURNAL; PROCTITIS; PROCTOCOLECTOMY; REMISSION; REVIEW; RISK FACTOR; SENESCENCE; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM; AGED; DIFFERENTIAL DIAGNOSIS; INFLAMMATORY BOWEL DISEASES;

AGED; ANTI-INFLAMMATORY AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 77954983523     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11537340-000000000-00000     Document Type: Review

References (84)

1. Loftus EV, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted county Minnesota 1940-1993: incidence, prevalence and survival. Gastroenterology 1998; 114: 1161-1168
2. Loftus EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted county Minnesota 1940-1993: incidence, prevalence and survival. Gut 2000; 46: 336-343
3. Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel disease in a northern California managed care organization, 1996-2002. Am J Gastroenterol 2008; 103: 1998-2006
4. Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999; 149: 916-924
5. Piront P, Louis E, Latour P, et al. Epidemiology of inflammatory bowel diseases in the elderly in the province of Liege: a three-year prospective study. Gastroenterol Clin Biol 2001; 25: 157-161
6. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 35: 690-697
7. Frangos C, Frangos C. Inflammatory bowel disease: reviewing an old study under a new perspective. Gut 2007; 56: 1638-1639
8. Yoshida Y, Murata Y. Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. Med Clin North Am 1990; 74: 67-90
9. Yang SK,Hong WS, Min YI, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol 2000; 15: 1037-1042
10. Fellows IW, Freeman JG, Holmes GKT. Crohn's disease in the city of Derby, 1951-1985. Gut 1990; 31: 1262-1265
11. Shivananda S, Lennard-Jones J, Logan R, the EC-IBD Study Group. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut 1996; 39: 690-697
12. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004; 99: 2393-2404
13. De Ridder L, Weersma RK, Dijkstra G, et al. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease. Inflamm Bowel Dis 2007; 13: 1083-1092
14. Tarrant KM, Barclay ML, Frampton CM, et al. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008; 103: 3082-3093
15. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128: 2020-2028
16. Somerville KW, Logan RF, Edmond M, et al. Smoking and Crohn's disease. BMJ 1984; 289 (6450): 954-956
17. Tobin MV, Logan RF, Langman MJ, et al. Cigarette smoking and inflammatory bowel disease. Gastroenterology 1987; 93: 316-321
18. Godet PG, May GR, Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995; 37: 668-673
19. Ekbom A, Adami HO, Helmick CG, et al. Perinatal risk factors for inflammatory bowel disease: a case-control study. Am J Epidemiol 1990; 132: 1111-1119
20. Koutroubakis IE, Vlachonikolis IG, Kapsoritakis A, et al. Appendectomy, tonsillectomy, and risk of inflammatory bowel disease: case-controlled study in Crete. Dis Colon Rectum 1999; 42: 225-230
21. Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci 1994; 39: 555-560
22. Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut 2002; 51: 808-813
23. Reif S, Lavy A, Keter D, et al. Appendectomy is more frequent but not a risk factor in Crohn's disease while being protective in ulcerative colitis: a comparison of surgical procedures in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 829-832
24. Klement E, Cohen RV, Boxman J, et al. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004; 80: 1342-1352
25. Baron S, Turck D, Leplat C, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 2005; 54: 357-363
26. Card T, Logan RF, Rodrigues LC, et al. Antibiotic use and the development of Crohn's disease. Gut 2004; 53: 246-250
27. Montgomery SM, Ekbom A. Epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol 2002; 18: 416-420
28. Boyko EJ, Koepsell TD, Perera DR, et al. Risk of ulcerative colitis among former and current cigarette smokers.NEngl J Med 1987; 316: 707-710
29. Freeman HJ. Age-dependent phenotypic clinical expression of Crohn's disease. J Clin Gastroenterol 2005; 39: 774-777
30. Freeman HJ. Application of the Vienna Classification for Crohn's disease to a single clinician database of 877 patients. Can J Gastroenterol 2001; 15: 89-93
31. Harper PC, McAuliffe TL, Beeken WL. Crohn's disease in the elderly: a statistical comparison with younger patients matched for sex and duration of disease. Arch Intern Med 1986; 146: 753-755
32. Farmer RG, Michener WM. Prognosis of Crohn's disease with onset in childhood or adolescence. Dig Dis Sci 1979; 24: 752-757
33. Polito JM, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and type of clinical disease. Gastroenterology 1996; 111: 580-586
34. Softley A, Myren J, Clamp SE, et al. Inflammatory bowel disease in the elderly patient. Scand J Gastroenterol 1988; 23: 27-30
35. Riegler G, Tartaglione MT, Carratu R, et al. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). Dig Dis Sci 2000; 45: 462-465
36. Zimmerman J, Gavish D, Rachmilewitz D. Early and late onset ulcerative colitis: distinct clinical features. J Clin Gastroenterol 1985; 7: 492-498
37. Greth J, Török HP, Koenig A, et al. Comparison of inflammatory bowel disease at younger and older age. Eur J Med Res 2004; 9: 552-554
38. Sinclair TS, Brunt PW, Mowat NA. Nonspecific proctocolitis in northern Scotland: a community study. Gastroenterology 1983; 85: 1-11
39. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis 2009; 15 (2): 182-189
40. Simon T. Epidemiology: is IBD different in the elderly? Inflamm Bowel Dis 2008; 14: 12-13
41. Lori AB, Stephen ER, Michael JG, et al. Hospitalized prevalence and 5-yearmortality for IBD: record linkage study. World J Gastroenterol 2010; 28 (16): 431-438
42. Talbot RW, Heppell J, Dozois RR, et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-145
43. Brackmann S, Andersen S, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol 2009; 44: 46-55
44. Triantafillidis JK, Emmanouilidis A, Nicolakis D, et al. Crohn's disease in the elderly: clinical features and longterm outcome of 19 Greek patients. Dig Liver Dis 2000; 32: 498-503
45. Wagtmans MJ, Verspaget HW, Lamers CB, et al. Crohn's disease in the elderly: a comparison with young adults. J Clin Gastroenterol 1998; 27: 129-133
46. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-1122
47. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayedrelease oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007; 21: 827-834
48. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137: 1934-1943
49. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57 (7): 893-902
50. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther 2008; 27: 1094-1102
51. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43
52. Loftus Jr EV. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis 2006; 12: 1107-1113
53. MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging 2005; 22: 231-255
54. Rodriguez-D'Jesus A, Casellas F, Malagelada JR. Epidemiology of inflammatory bowel disease in the elderly. Gastroenterol Hepatol 2008; 31: 269-273
55. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe steroid refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-88
56. Rutgeerts P, Sandborn WJ, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476 (Pubitemid 41770166)
57. Stange EF, Travis S. The European consensus on ulcerative colitis: new horizons? Gut 2008; 57: 1029-1031
58. Kornbluth A, Present DH, Lichtiger S, et al. Cyclosporine for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997; 92: 1424-1428
59. Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. AmJGastroenterol 1996; 91: 2498-2499
60. Almogy G, Sachar DB, Bodian C, et al. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch Surg 2001; 136: 1396-1400
61. Grimm IS, Friedman LS. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am 1990; 19: 361-389
62. Brandt LJ, Dickstein G. Inflammatory bowel disease: specific concerns in the elderly. Geriatrics 1989; 44: 107-111
63. Stephan RV, Gerhard R. Treatment of severe ulcerative colitis: differences in elderly patients?Dig Dis 2009; 27: 315-321
64. Peter A, Johan D, Soderholm J. Surgery in ulcerative colitis: indication and timing. Dig Dis 2009; 27: 335-340
65. Vavricka S, Rogler G. Treatment of severe ulcerative colitis: differences in the elderly patients? Dig Dis 2009; 27: 315-321
66. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 320-327
67. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204: 956-962
68. Mor IJ, Vogel JD, da Luz MA, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008; 51: 1202-1207
69. Michael JP, Lisa SP, Susan J, et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg 2002; 6 (4): 606-613
70. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339: 370-374
71. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
72. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333
73. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238
74. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838
75. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
76. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; (2): CD000067
77. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-297
78. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-266
79. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 936-939
80. Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol 2005; 17: 145-147
81. Picco MF, Cangemi JR. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am 2009; 38: 447-462
82. Witte TN, Ginsberg AL. Use of allopurinol with low-dose 6- mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol 2008; 22: 181-185
83. Brooks RJ, Dorr RT, Durie BG. Interaction of allopurinol with 6-mercaptopurine and azathioprine. Biomed Pharmacother 1982; 36: 217-222
84. Toruner M, Loftus E, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936